Ann: Promising Interim Results from TAVR Animal Study, page-22

This is a very interesting stock, it's MC value and market sentiment is like a start-up bio-stock, but they have commercialize products so they've gone through all that dilution to raise funds to get their product to this stage, allowing them to have a significant revenue stream but this is cancel out by their equally extremely significant non-director/management employee salaries, and WP is on the nose.
Because of this, worst case scenario, WP gets sacked, most of the non-director/management employees get sacked and they start again as a bio-stock startup with MC of $20M and minimal operation cost, sell their other assets IP and start again with IMMO and TAVR.